R. Steigerwald

P18-12 LB. Phase I clinical trial with a new recombinant MVA-BN®-multiantigen vaccine: high responder rate and considerable breadth of immunological response (2009)

Overton, T, Schmidt, D, Hain, J, Virgin, G, Steigerwald, R, Dirmeier, U, ...

No abstract available.

Hammerhead ribozymes with cleavage site specificity for NUH and NCH display significant anti-hepatitis C viral effect in vitro and in recombinant HepG2 and CCL13 cells (2006)

Gonzalez-Carmona, M. A., Schussler, S., Serwe, M., Alt, M., Ludwig, J., Sproat, B. S., ...

Requirements for adeno-associated virus-derived non-viral vectors to achieve stable and site-specific integration of plasmid DNA in liver carcinoma cells (2003)

Steigerwald,R., Rabe,C., Schmitz,V., Schmidt-Wolf,I. G., Alt,M., Caselmann,W. H.

Requirements for adeno-associated virus-derived non-viral vectors to achieve stable and site-specific integration of plasmid DNA in liver carcinoma cells (2003)

Steigerwald, R., Rabe, C., Schmitz, V., Schmidt-Wolf, I. G., Alt, M., Caselmann, W. H.

Hydration scanning tunneling microscopy of dna and a bacterial surface protein (1997)

Heim, M., Steigerwald, R., Guckenberger, R.

Hydration scanning tunneling microscopy is based on the electrical conductivity of molecularly thin water layers which adsorb to the sample surfaces in a humid atmosphere. It allows reliable imaging...

P18-12 LB. Phase I clinical trial with a new recombinant MVA-BN®-multiantigen vaccine: high responder rate and considerable breadth of immunological response

Overton, T, Schmidt, D, Hain, J, Virgin, G, Steigerwald, R, Dirmeier, U, ...